Vanillalite
Ask me about the GAF Notebook
Forbes
23andMe, a genetic testing startup that captured the national imagination a decade ago, appears to have fully emerged from the wilderness. The Food and Drug Administration has cleared the startup to market $199 genetic tests that will tell consumers not whether they have a condition like Parkinson's or Alzheimer's, but how likely they might be to get it.
In November 2013, 23andMe provided people who purchased its test kits, spit in a vial and mailed it in information on 254 health conditions. Then the FDA required the company to withdraw all its tests for genetic risks related to health from the market because the company had not established the efficacy of its tests and had gone silent on regulators. In February 2015, the FDA cleared 23andMe to provide consumers with information about genes they might carry that might affect their future children. But the bar was lifted even further today, particularly because the FDA says it intends to grant 23andMe and exemption that will allow it to introduce new tests far more easily.
Experts had mixed responses to the decision. George Demetri, director of the Center for Sarcoma and Bone Oncology at the Dana-Farber Cancer Institute, praised the FDA for "thinking ahead and accelerating progress" in a tweet. Anirban Maitra, scientific director of the Ahmed Center for Pancreatic Cancer at M.D. Anderson Cancer Center, tweeted, "The potential for quackery & snake oil salesmanship this will result in is mind boggling."
"It could be worse," says Hank Greely, director of the Center for Law and the Biosciences. "It might not be a bad thing. Im not enthusiastic. Im not convinced this will improve Americans' health or make consumers better off. But Im not convinced that it wont."
One reality is that the science around such tests has changed since the FDA's original action, which was caused as much by 23andMe's clumsy refusal to respond to the FDA's queries as by the science. "Since that whole debacle at the FDA, many genetic risk scores have been published, in top-tier journals," says Eric Topol, director of the Scripps Translational Research Institute in La Jolla, Calif. "This whole idea of genomic risk for common diseases is a real deal. I think 23andMe and other companies provide information and education; I think thats a good public service."
The disorders that will be included in the test are, verbatim from the FDA press release:
Parkinsons disease, a nervous system disorder impacting movement
Late-onset Alzheimers disease, a progressive brain disorder that destroys memory and thinking skills
Celiac disease, a disorder resulting in the inability to digest gluten
Alpha-1 antitrypsin deficiency, a disorder that raises the risk of lung and liver disease
Early-onset primary dystonia, a movement disorder involving involuntary muscle contractions and other uncontrolled movements
Factor XI deficiency, a blood clotting disorder
Gaucher disease type 1, an organ and tissue disorder
Glucose-6-Phosphate Dehydrogenase deficiency, also known as G6PD, a red blood cell condition
Hereditary hemochromatosis, an iron overload disorder
Hereditary thrombophilia, a blood clot disorder